The company remains a pure-play R&D entity with negligible revenue, as demonstrated by the 2026Q1 gross loss of $32,000 and the absence of any meaningful commercial product footprint.
| Sales/Revenue | 0 | 39.99K | 83K | 70.46K | 20K | 0 |
| Revenue Growth % | - | - | 17.79% | 252.31% | - | - |
| Cost of Goods Sold | 31.98K | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | -31.98K | 39.99K | 83K | 70.46K | 20K | 0 |
| Gross Margin % | - | 100% | 100% | 100% | 100% | - |
| Gross Profit Growth % | - | - | 17.79% | 252.31% | - | - |
| Operating Expenses | 33.36M | 58.21M | 7.23M | 12.27M | 2.86M | 3.27M |
| OpEx % of Revenue | - | 145559.36% | 8705.45% | 17410.99% | 14288.02% | - |
| Selling, General & Admin | 20.02M | 42.85M | 3.64M | 3.4M | 1.69M | 2.6M |
| SG&A % of Revenue | - | 107162.72% | 4384.38% | 4819.97% | 8471.37% | - |
| Research & Development | 3.93M | 3.64M | 3.05M | 1.53M | 1.16M | 674.56K |
| R&D % of Revenue | - | 9097.92% | 3668.96% | 2177.22% | 5816.65% | - |
| Other Operating Expenses | 2.05M | 11.72M | 541.25K | 7.34M | 0 | 0 |
| Operating Income | -33.4M | -58.17M | -7.14M | -12.2M | -2.84M | -3.27M |
| Operating Margin % | - | -145459.36% | -8605.45% | -17310.99% | -14188.02% | - |
| Operating Income Growth % | - | - | 41.44% | -329.86% | 13.27% | - |
| EBITDA | -33.82M | -58.13M | -6.9M | -12.2M | -2.85M | -3.26M |
| EBITDA Margin % | - | -145368.18% | -8309.13% | -17310.99% | -14233.02% | - |
| EBITDA Growth % | - | - | 43.46% | -328.5% | 12.75% | - |
| D&A (Non-Cash Add-back) | 50.29K | 36.46K | 245.94K | 0 | 0 | 0 |
| EBIT | -34.68M | -59.64M | -9.34M | -12.2M | -2.85M | -3.26M |
| Net Interest Income | -2.92M | -2.18M | -2.69M | -2.72M | -200.15K | -112.92K |
| Interest Income | 281.08K | 327.58K | 16.13K | 0 | 0 | 0 |
| Interest Expense | 3.2M | 2.5M | 2.7M | 2.72M | 200.15K | 112.92K |
| Other Income/Expense | -5.24M | -3.98M | -4.76M | -2.72M | -209.15K | -103.92K |
| Pretax Income | -38.64M | -62.15M | -11.9M | -14.92M | -3.05M | -3.38M |
| Pretax Margin % | - | -155404.38% | -14335.5% | -21176.05% | -15233.78% | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -38.64M | -62.15M | -11.9M | -14.92M | -3.05M | -3.38M |
| Net Margin % | - | -155404.38% | -14335.5% | -21176.05% | -15233.78% | - |
| Net Income Growth % | - | - | 20.26% | -389.74% | 9.74% | - |
| Net Income (Continuing) | -38.64M | -62.15M | -11.9M | -14.92M | -3.05M | -3.38M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.66 | -3.23 | -0.63 | -0.80 | -0.16 | -0.18 |
| EPS Growth % | - | - | 21.25% | -400% | 11.11% | - |
| EPS (Basic) | - | -3.23 | -0.63 | -0.80 | -0.16 | -0.18 |
| Diluted Shares Outstanding | 23.29M | 19.21M | 18.75M | 18.75M | 18.75M | 18.75M |
| Basic Shares Outstanding | 23.29M | 19.21M | 18.75M | 18.75M | 18.75M | 18.75M |
| Dividend Payout Ratio | - | - | - | - | - | - |
Imminent liquidity exhaustion risk
As indicated by the company's financial disclosures, NTHI currently lacks a recurring revenue stream, with reported figures showing sporadic, non-operational income that peaked at $43,000 in 2024Q1, confirming the firm remains a pure-play R&D entity without any established commercial product footprint or predictable growth trajectory.
The intermittent revenue entries suggest that the company has not yet achieved commercial viability, rendering traditional growth analysis inapplicable. Investors should monitor future regulatory milestones rather than top-line expansion, as the current revenue profile is entirely dependent on non-core licensing or grant activity.
According to the provided income statement data, NTHI's cost structure is dominated by heavy R&D and SG&A expenditures, which reached a combined quarterly peak of $25.9 million in 2025Q1, highlighting an aggressive spending profile that significantly outpaces the company's negligible revenue generation capabilities.
The volatility in SG&A expenses, particularly the spike observed in early 2025, suggests that the company is incurring substantial costs related to clinical trial infrastructure and regulatory compliance. This expense discipline appears secondary to the urgent requirement of advancing the NEO100 pipeline, which necessitates high cash outflows regardless of the current lack of commercial scale.
Based on reported financial statements, NTHI's net income is heavily impacted by significant stock-based compensation, which reached $23.1 million in 2025Q1, suggesting that reported losses may be partially driven by non-cash accounting charges rather than purely operational cash outflows during that specific reporting period.
The reliance on equity-based incentives for personnel suggests a strategy to preserve limited cash, yet it complicates the assessment of true operational efficiency. Analysts should adjust for these non-cash items to better understand the underlying burn rate and the actual runway remaining for clinical development.
As evidenced by the reported cash balance of $58,729 against multi-million dollar quarterly operating losses, NTHI faces a severe liquidity crisis that warrants extreme caution, as the current financial position appears insufficient to sustain the ongoing Phase 2a clinical trials without immediate and substantial external capital.
The disconnect between the company's ambitious clinical development goals and its reported cash reserves suggests a high probability of significant shareholder dilution in the near term. Investors should monitor for potential financing announcements, as the current capital structure appears unable to support the firm's stated R&D objectives.
Quick answers to the most common questions about buying NTHI stock.
For fiscal year 2025, Neonc Technologies Holdings, Inc. (NTHI) reported total revenue of $0.0M.
Neonc Technologies Holdings, Inc. (NTHI) reported a net loss of $62.1M for the fiscal year ending 2025.
Neonc Technologies Holdings, Inc. (NTHI) reported an operating income of $-58.2M, resulting in an operating profit margin of -145459.4%. This margin reflects the operational efficiency of the business before interest and taxes.
Neonc Technologies Holdings, Inc. (NTHI) generated $0.0M in gross profit for the year, representing a gross profit margin of 100.0%. This demonstrates the company's core pricing power and production efficiency.